The Fidelity MSCI Health Care Index ETF (FHLC) has declined about 5% year-to-date, while the S&P 500 has risen 7%, and over five years FHLC returned 15% versus 80% for the S&P 500. FHLC tracks a broad healthcare index with 342 holdings but is heavily concentrated in a few large pharma stocks like Eli Lilly, which risks performance if those stocks falter. The fund offers low fees and modest dividends but has underperformed due to healthcare's slower growth compared to tech sectors. Investors seeking healthcare exposure might consider biotech or nursing home REITs, which have shown stronger returns. FHLC may suit a small defensive portfolio allocation but is not ideal as a core growth investment.
Eli Lilly's next-generation obesity drug, retatrutide, achieved significant weight loss in a late-stage trial, with patients losing up to 28.3% of their body weight over 80 weeks. The drug, which targets three gut hormones, outperformed existing trea...
Incyte has signed a $120 million partnership with Genesis Molecular AI, including $80 million upfront and a $40 million equity investment, to advance AI-driven drug discovery. This deal could exceed $1 billion with future milestones and royalties, us...
Eli Lilly has filed a civil lawsuit alleging a $200 million rebate fraud scheme involving several bishops of the Church of God in Christ and a Florida mail-order pharmacy, DrugPlace. The scheme involved false claims for rebates on the diabetes drug T...
The iShares U.S. Pharmaceuticals ETF (IHE) has gained 38% over the past year despite threats from U.S. drug pricing policies like the 'most favored nation' order. The ETF benefits from dividends and strong drug pipelines, especially from major holdin...
Eli Lilly demonstrates strong bullish technical indicators including price action, momentum, and relative strength, supporting a continued uptrend. Despite receiving an 'F' valuation grade, the company's growth, profitability, and upward earnings rev...
